Pondera Scientific Advisory Board
Eric J. Simon, Ph.D. (In 1976, Dr. Simon coined the word “endorphins”.)
New York, NY 10016
1951 — Dr. Simon received his Ph.D. degree in Organic Chemistry from the University of Chicago, Chicago, IL, Graduate Education
1951-1953 — Dr. Simon was a Postdoctoral Fellow in Biochemistry at Columbia University, College of Physicians & Surgeons, New York, NY, PostDoctoral Training
Our research explores the neurochemistry of neuropeptides and their receptors with the main objective of understanding the structure and functions of the endogenous opioid system, i.e., opioid receptors and endogenous opioid peptides. We discovered opioid receptors in 1973 and continue to contribute actively to this area with an interdisciplinary investigative approach from molecular biology to behavioral pharmacology.
Part of our work is characterizing the major types of opioid receptors, mu, delta, and kappa. We showed that the binding proteins of these receptors can be separated by size; we also purified to homogeneity the mu binding site from bovine brain and have cloned this receptor. We reconstituted the mu binding protein, purifies from bovine brain in liposomes with G-protein, resulting in the restoration of selective, GTP-sensitive, high affinity mu agonist binding, and mu-specific stimulation of GTPase activity.
We also study receptor regulation by phosphorylation and sequestration, the nature of the sugar moieties of this glycoprotein and, by quantitative autoradiography, pathophysiological changes in opioid receptors. The cloning of the major opioid receptors makes available cDNA for studies, including determining regions involved in receptor activation and G-protein coupling, by site-directed mutagenesis and regulation of receptor gene expression, by in situ hybridization. Proteins that intertact with the carboxyl tail of the mu opioid receptor are under study. We also have an active program on opioid signaling via the MAP kinase pathway.
Neuropeptides and Their Receptors
neuropeptides, opioids, receptors, signal transduction, site-directed mutagenesis
Elliot J. Krane, MD
- Anesthesia, Pediatric
- Complex Regional Pain Syndromes
- Professor, Anesthesia, Stanford University School of Medicine (1994 – present)
- Professor, Pediatrics, Stanford University School of Medicine (1994 – present)
- Chief of Pain Management Service, LPCH (1994 – present)
- Chief of Anesthesia, LPCH (1994 – 2003)
- Associate Professor, Anesthesiology, University of Washington (1989 – 1994)
Honors and Awards
- Mayday Pain & Society Fellowship, Mayday Fund (2010)
- Diagnosis and Treatment of Complex Regional Pain Syndromes in Childhood, Mayday Fund (2008)
- Phi Beta Kappa, Reed College (1974)
- Alpha Omega Alpha, University of Arizona (1977)
- Cerebral blood flow in an infant animal model, American Society of Anesthesiologists (1984)
|Fellowship:||Children’s Hospital Boston MA (1983)|
|Residency:||Massachusetts General Hospital MA (1982)|
|Residency:||Massachusetts General Hospital MA (1980)|
|Internship:||Massachusetts General Hospital MA (1979)|
|Recertification:||American Board of Anesthesiology , Anesthesia (2009)|
Graduate & Fellowship Program Affiliations
Community & International Work
- Surgery in Nicaragua, Esteli, Nicaragua
- Taiwan National Children’s Hospital, Taipei
- Project Hope, Former states of the Soviet Union
Current Research Interests
The management of pain in children using intraspinal opioids, regional anesthetics, and novel analgesic agents; cerebral and osmolar complications of diabetic ketoacidosis in children.
- Pediatric Regional Anesthesia Network (PRAN): The use of and complications in pediatric regional anesthesia Recruiting
- IV APAP PK study No longer recruiting
- Measuring the amount of Methadone or Morphine in the blood of neonates, infants & children after cardiac surgery. Completed
- Neuropathic pain in children: Special considerations. Walco GA, Dworkin RH, Krane EJ, LeBel AA, Treede RD. Mayo Clin Proc. 2010; 85 (3 Suppl): S33-41
- Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Dworkin RH, O’Connor AB, Audette J, Baron R, Gourlay GK, Haanpää ML, Kent JL, Krane EJ, Lebel AA, Levy RM, Mackey SC, Mayer J, Miaskowski C, Raja SN, Rice AS, Schmader KE, Stacey B, Stanos S, Treede RD, Turk DC, Walco GA, Wells CD. Mayo Clin Proc. 2010; 85 (3 Suppl): S3-14
- A comparison of the clinical utility of pain assessment tools for children with cognitive impairment. Voepel-Lewis T, Malviya S, Tait AR, Merkel S, Foster R, Krane EJ, Davis PJ. Anesth Analg. 2008; 106 (1): 72-8, table of contents
- Patient-controlled analgesia: proxy-controlled analgesia? Krane EJ, Anesth Analg. 2008; 107 (1): 15-7
- Non-pharmacological techniques for pain management in neonates. Golianu B, Krane E, Seybold J, Almgren C, Anand KJ. Semin Perinatol. 2007; 31 (5): 318-22
Lynn R. Webster, MD, FACPM, FASAM
Medical Director and Founder, Lifetree Clinical Research® & Pain Clinic
Director-At-Large for the American Academy of Pain Medicine
Dr. Lynn Webster is co-founder and chief medical director of Lifetree Clinical Research®. His research interests are diverse. He is keenly interested in working with industry to develop safer and more effective therapies for chronic pain and addiction. He is a leading researcher in exploring the relationship of medications and sleep, with particular interest in analgesic-induced sleep-disordered breathing.
Dr. Webster is board certified in anesthesiology and pain medicine and is also certified in addiction medicine. He earned his doctorate of medicine from the University of Nebraska Medical Center and completed his residency in the University of Utah Medical Center’s department of anesthesiology.
He lectures extensively on the subject of preventing opioid abuse and criminal diversion in chronic pain patients, and has authored numerous scientific abstracts, journal articles, textbook chapters, and a book entitled Avoiding Opioid Abuse While Managing Pain: A Guide for Practitioners. This book was written for clinicians as a guide to sort out the clinical, regulatory, and ethical issues associated with the prescribing of opioid analgesics. It includes step-by-step protocols for assessing patients for the risk of opioid abuse as well as for legally protecting the opioid prescriber. Dr. Webster is co-editor of Pain Medicine’s section on opioids, substance abuse, and addiction and serves as a reviewer for numerous peer-reviewed journals. He was the Interventional Therapies section editor for Practical Pain Management for 2006 and 2007.
Dr. Webster co-founded LifeSource, a non-profit foundation established in 2006 to educate physicians, patients and communities on health issues (with an emphasis on pain-related, scientific and social issues), as well as to fund and conduct research to discover new solutions and hope for improved life. LifeSource’s first project is entitled “Zero Unintentional Deaths.” The campaign was developed to educate physicians, chronic pain sufferers and all communities about the increasingly serious issue of unintentional overdose deaths relating to methadone and other prescription medications, and it aims to eliminate unintentional overdoses from prescribed methadone. His medical expertise has contributed to national news stories addressing the dangers of methadone and other prescription medications, including ABC News’ 20/20 program on Friday, September 22, 2006, and Court TV’s Catherine Crier Live on Wednesday, September 27, 2006.
Dr. Webster is currently on the board of directors for the American Academy of Pain Medicine and was instrumental in launching the Utah chapter. This organization seeks to achieve high medical standards, improve access to pain care and educate all interested parties about the many pain-related scientific and social issues.
Department of Neurology & Neurosciences
|One primary interest is the function of GM1 and other gangliosides in the nervous system; this involves several aspects of calcium regulation. Absence of GM1 induces epilepsy. We also study myelin in relation to N-acetylaspartate that contributes to myelin lipid synthesis, and demyelination by autoimmune mechanisms.|